Study design and patients
anti-AChR, Myasthenia Gravis
MENINGOCOCCAL INFECTION, DISEASE, MYASTHENIA GRAVIS
The CHAMPION MG study consists of a 26-week, double-blind, randomized, placebo-controlled period (RCP), followed by an ongoing OLE of up to 4 years (Fig. Study design. IV, intravenous. From NEJM Evidence, Vu T, et al, Terminal complement inhibitor ravulizumab in generalized myasthenia gravis, 1, EvidDoa2100066. Copyright © 2022 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical SocietyAdult patients (≥ 18 years of age), diagnosed with MG ≥ 6 months before screening and who were anti-AChR antibody-positive, were included in the study. Additionally, patients had to have Myasthenia Gravis Foundation of America class II–IV disease and a Myasthenia Gravis–Activities of Daily Living (MG-ADL) total score of ≥ 6 at screening and randomization. As patients treated with C5 inhibitors are at increased risk of meningococcal infection, all participants were required to be vaccinated against 